Medical Developments International Limited

MVP.ASX

Health Care

Pharmaceutical drug business and medical and veterinary equipment business.

Market Data

Price

$0.385

-0.0%
Market Cap

$43.4M

P/E Ratio

-100000.0x

EPS

$-0.004

Div. Yield

0.00%

52-Week Change

-0.3%

Latest Earnings

FY26 Half Year Report (including Appendix 4D)

19 February 2026

Revenue
$21.60
+8.0% YoY
NPAT
-$0.23
-174.3% YoY
EPS
$-0.00

Medical Developments International reported a loss of $0.2 million in H1 FY26 compared to a $0.3 million profit in the prior period, despite 8% revenue growth to $21.6 million. Pain Management segment performed strongly with 18% revenue growth driven by volume increases, while Respiratory revenue declined 10% due to softer US demand. Key points: Pain Management revenue up 18% driven by volume growth, with hospital segment demand up 26%; Continued growth of Penthrox in Europe with in-market volumes up 10% across all regions; Strong cash position of $16.9 million with positive operating cash flow of $0.3 million

Recent Announcements

19 Feb 2026 Actual Results Neutral

FY26 Half Year Report (including Appendix 4D)

Medical Developments International reported a loss of $0.2 million in H1 FY26 compared to a $0.3 million profit in the prior period, despite 8% revenue growth to $21.6 million. Pain Management segment performed strongly with 18% revenue growth driven by volume increases, while Respiratory revenue declined 10% due to softer US demand. Key points: Pain Management revenue up 18% driven by volume growth, with hospital segment demand up 26%; Continued growth of Penthrox in Europe with in-market volumes up 10% across all regions; Strong cash position of $16.9 million with positive operating cash flow of $0.3 million

Get real-time alerts for MVP

Receive AI-powered earnings summaries and instant notifications when Medical Developments International Limited releases results.

Register Free